| Literature DB >> 34040703 |
Omar Elshaarawy1, Aya Aman1, Hazem Mohamed Zakaria2, Talaat Zakareya1, Asmaa Gomaa1, Esam Elshimi3, Eman Abdelsameea1.
Abstract
BACKGROUND: Given the poor synthetic function of cirrhotic liver, successful resection for patients with hepatocellular carcinoma (HCC) necessitates the ability to achieve resections with tumor free margins. AIM: To validate post hepatectomy liver failure score (PHLF), compare it to other established systems and to stratify risks in patients with cirrhosis who underwent curative liver resection for HCC.Entities:
Keywords: Cirrhosis; Hepatocellular carcinoma; Liver; Resection; Scores
Year: 2021 PMID: 34040703 PMCID: PMC8131904 DOI: 10.4251/wjgo.v13.i5.424
Source DB: PubMed Journal: World J Gastrointest Oncol
Pre-operative demographics and baseline characteristics of the study population
|
|
|
| Age in years (mean ± SD) | 59.23 ± 6.52 |
| HCV-related liver disease, | 105 (87.5) |
| Hypertensive, | 34 (28.3) |
| Diabetic, | 36 (30) |
| Previous abdominal operations, | 34 (28.3) |
| Child-Pugh class, | |
| A5 | 90 (75) |
| A6 | 30 (25) |
| MELD score (mean ± SD) | 8.54 ± 1.78 |
| MELD score, | |
| < 10 | 90 (75) |
| 10-20 | 30 (25) |
| BCLC stage, | |
| 0 | 12 (10) |
| A | 72 (60) |
| B | 36 (30) |
| Pre-operative upper endoscopy | |
| Oesophageal Varices, | |
| No | 78 (65) |
| Yes | 42 (35) |
| Pre-operative imaging | |
| Diameter of largest tumor in cm (mean ± SD) | 4.57 ± 2.03 |
| Tumor diameter > 5 cm, | |
| No | 86 (71.7) |
| Yes | 34 (28.3) |
| Serum Bilirubin (mg/dL) | 0.87 ± 0.34 |
| Aspartate Aminotransferase (U/L) | 53.2 ± 29.6 |
| Alanine Aminotransferase (U/L) | 44.32 ± 25.65 |
| Serum Albumin (g/dL) | 3.78 ± 0.48 |
| International normalized ratio | 1.16 ± 0.1 |
| Serum creatinine (mg/dL) | 0.86 ± 0.22 |
| Platelets count ( 103/mm3) | 141 ± 64.32 |
| Serum AFP (ng/mL) | 193.37 ± 343.37 |
| Serum AFP (ng/mL), | |
| < 20 | 52 (43.3) |
| 20-400 | 30 (25) |
| > 400 | 20 (16.7) |
| Undocumented | 18 (15) |
| Platelets < 150.000/mm3, | 64 (53.3) |
| Anatomical resection, | 22 (18.3) |
| Use of Harmonic scalpel, | 40 (33.3) |
| Use of Habib sealer, | 40 (33.3) |
| Use of CUSA, | 2 (1.7) |
| Intraoperative bleeding, | 4 (3.3) |
| Blood transfusion, | 12 (10) |
| Plasma transfusion, | 6 (5) |
| Grade of differentiation, | |
| 1 or 2 | 58 (48.3) |
| 3 or 4 | 38 (31.7) |
| Undocumented | 24 (20) |
| Lymph/vascular invasion, | 44 (36.7) |
HCV: Hepatitis C virus; MELD: Model for end-stage liver disease; BCLC: Barcelona clinic liver cancer; AFP: Alpha-fetoprotein; CUSA: Cavitron Ultrasonic Surgical Aspirator.
Post-operative data and complications after resection in the study population
|
|
|
| Serum bilirubin (mg/dL) | 1.5 ± 0.64 |
| AST (U/L) | 29.95 ± 11.31 |
| ALT (U/L) | 20.51 ± 10.03 |
| Serum albumin (g/dL) | 3.21 ± 0.41 |
| INR | 1.25 ± 0.14 |
| Serum Creatinin (mg/dL) | 0.87 ± 0.23 |
| Serum AFP (ng/mL) | 2109.7 ± 10795.17 |
| CRP (mg/L) | 45.99 ± 31.19 |
| Length of the hospital stay (d) | 8.9 ± 5.05 |
| ICU stay (d) | 4.28 ± 4.19 |
| Child-Pugh score | |
| On discharge | 6.62 ± 1.54 |
| 3-mo post-operative | 6.51 ± 1.1 |
| MELD score | 10.63 ± 2.27 |
| ICU stay, | 58 (48.3) |
| MELD score, | |
| ≤ 10 | 68 (56.7) |
| > 10 | 52 (43.3) |
| 50-50 criteria, | |
| Absent | 116 (96.7) |
| Present | 4 (3.3) |
| PHLF, | |
| Absent | 76 (63.3) |
| Grade A | 16 (13.3) |
| Grade B | 22 (18.3) |
| Grade C | 6 (5) |
| Post-operative complications, | |
| Hemorrhage | 4 (3.3) |
| Bile leak | 2 (1.7) |
| Wound infection | 4 (3.3) |
| Chest infection | 14 (11.7) |
| Recurrence of HCC, | 34 (28.3) |
| Post-operative decompensation, | 50 (41.7) |
| Peri-operative mortality, | 4 (3.3) |
| Overall survival, | |
| Alive | 70 (58.3) |
| Died | 50 (41.7) |
HCC: Hepatocellular carcinoma; MELD: Model for end-stage liver disease; PHLF: Post-hepatectomy liver failure; ICU: Intensive care units; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; INR: International normalized ratio; CRP: C-reactive protein.
Univariate analysis of pre-operative, operative and post-operative factors predictive of hepatic decompensation after liver resection for hepatocellular carcinoma (calculated at 3 mo post-operative)
|
|
|
|
|
|
| Age, | ||||
| < 60 yr | 36 (58.1) | 26 (41.9) | 0.004 | 0.951 |
| ≥ 60 yr | 34 (58.6) | 24 (41.0) | ||
| Antiviral therapy for HCV, | ||||
| No treatment | 34 (46.6) | 39 (53.4) | 29.143 | < 0.001 |
| DAAs | 34 (82.9) | 7 (17.1) | ||
| Interferon | 2 (33.3) | 4 (66.7) | ||
| Clinically significant portal hypertension, | ||||
| No | 52 (66.7) | 26 (33.3) | 7.7 | 0.006 |
| Yes | 17 (40.5) | 25 (59.5) | ||
| BCLC stage, | ||||
| 0 | 12 (100) | 0 (0) | 40.0 | < 0.001 |
| A | 52 (72.2) | 20 (27.8) | ||
| B | 6 (16.7) | 30 (83.3) | ||
| MELD score, | ||||
| < 10 | 60 (68.2) | 28 (31.8) | 22.721 | < 0.001 |
| 10-20 | 4 (15.4) | 22 (84.6) | ||
| Pre-operative Child-Pugh score, | ||||
| A5 | 54 (60) | 36 (40) | 0.411 | 0.521 |
| A6 | 16 (53.3) | 14 (46.7) | ||
| AFP (ng/mL), | ||||
| < 20 | 30 (57.7) | 22 (42.3) | 3.509 | 0.173 |
| 20-400 | 20 (66.7) | 10 (33.3) | ||
| > 400 | 8 (40) | 12 (60) | ||
| Pre-operative serum bilirubin (mg/dL), | ||||
| ≤ 1 | 46 (57.5) | 34 (42.5) | 0.201 | 0.654 |
| > 1 | 18 (52.9) | 16 (47.1) | ||
| Tumor diameter > 5 cm, | ||||
| No | 64 (74.4) | 22 (25.6) | 32.311 | < 0.001 |
| Yes | 6 (17.6) | 28 (82.4) | ||
| Number of tumors, | ||||
| Single | 68 (60.7) | 44 (39.3) | 5.869 | 0.027 |
| More than one | 0 (0) | 4 (100) | ||
| Site of tumor(s), | ||||
| Right lobe | 36 (62.1) | 22 (37.9) | 1.626 | 0.443 |
| Left lobe | 32 (57.1) | 24 (42.9) | ||
| Bilobar | 2 (100) | 0 (0) | ||
| Milan criteria, | ||||
| Within | 36 (69.2) | 16 (30.8) | 15.537 | < 0.001 |
| Beyond | 8 (25) | 24 (75) | ||
| Tumor differentiation, | ||||
| Grade 1 or 2 | 38 (63.3) | 22 (36.7) | 1.646 | 0.2 |
| Grade 3 or 4 | 18 (50) | 18 (50) | ||
| Lymph/vascular invasion, | ||||
| No | 38 (70.4) | 16 (29.6) | 8.593 | 0.003 |
| Yes | 18 (40.9) | 26 (59.1) | ||
| Type of resection, | ||||
| Open | 28 (42.4) | 38 (57.6) | 13.473 | < 0.001 |
| Laparoscopic | 12 (100) | 0 (0) | ||
| Anatomical resection, | ||||
| No | 38 (57.6) | 28 (42.4) | 0.978 | 0.323 |
| Yes | 10 (45.5) | 12 (54.5) | ||
| Extension of hepatectomy, | ||||
| One segment | 30 (51.7) | 28 (48.3) | 2.241 | 0.326 |
| Two segments | 8 (44.4) | 10 (55.6) | ||
| Three segments | 2 (100) | 0 (0) | ||
| ICU admission, | ||||
| No | 44 (71) | 18 (29) | 8.425 | 0.004 |
| Yes | 26 (44.8) | 32 (55.2) | ||
| Postoperative complications, | ||||
| Hemorrhage | 4 (100) | 0 (0) | 2.956 | 0.14 |
| Bile leak | 0 (0) | 2 (100) | 2.847 | 0.172 |
| Wound infection | 0 (0) | 4 (100) | 5.793 | 0.028 |
| Chest infection | 2 (14.3) | 12 (85.7) | 12.652 | < 0.001 |
| PHLF, | ||||
| Absent | 54 (71.1) | 22 (28.9) | 22.305 | < 0.001 |
| Grade A | 10 (62.5) | 6 (37.5) | ||
| Grade B | 6 (27.3) | 16 (72.7) | ||
| Grade C | 0 (0) | 6 (100) | ||
| 50-50 criteria, | ||||
| Absent | 70 (60.3) | 46 (39.7) | 5.793 | 0.028 |
| Present | 0 (0) | 4 (100) | ||
| HCC recurrence, | 16 (47.1) | 18 (52.9) | 2.481 | 0.115 |
|
|
|
|
| |
|
| ||||
| Post-operative bilirubin (mg/dL) | 1.21 ± 0.49 | 1.98 ± 0.57 | -7.353 | < 0.001 |
| Post-operative AFP (ng/mL) | 3020.12 ± 13277.79 | 371.63 ± 761.79 | 0.931 | 0.355 |
| Post-operative Child-Pugh score | 5.78 ± 0.65 | 7.62 ± 0.58 | -14.768 | < 0.001 |
| Age | 58.77 ± 6.68 | 59.88 ± 6.29 | -0.918 | 0.36 |
| Pre-operative Bilirubin (mg/dL) | 0.87 ± 0.31 | 0.87 ± 0.38 | 0.007 | 0.994 |
| Pre-operative MELD score | 8.03 ±1.44 | 9.2 ± 1.96 | -3.541 | 0.001 |
| Pre-operative Child score | 5.23 ± 0.42 | 5.28 ± 0.45 | -0.637 | 0.525 |
| Pre-operative AFP (ng/mL) | 149.58 ± 239.28 | 251.09 ± 441.64 | -1.379 | 0.173 |
| Tumor diameter (cm) | 3.77 ± 1.32 | 5.68 ± 2.33 | -5.238 | < 0.001 |
| ICU stay (d) | 2.92 ± 1.35 | 5.38 ± 5.29 | -2.522 | 0.016 |
| Hospital stay (d) | 6.86 ± 2.08 | 11.26 ± 6.34 | -4.092 | < 0.001 |
| Post-operative bilirubin (mg/dL) | 1.21 ± 0.49 | 1.98 ± 0.57 | -7.353 | < 0.001 |
| Post-operative AFP (ng/mL) | 3020.12 ± 13277.79 | 371.63 ± 761.79 | 0.931 | 0.355 |
| Post-operative Child-Pugh score | 5.78 ± 0.65 | 7.62 ± 0.58 | -14.768 | < 0.001 |
P < 0.05.
P < 0.01.
P < 0.001.
AFP: Alpha-fetoprotein; BCLC: Barcelona clinic liver cancer; HCC: Hepatocellular carcinoma; MELD: Model for end-stage liver disease; PHLF: Post-hepatectomy liver failure; ICU: Intensive care units; HCV: Hepatitis C virus; DAAs: Direct-acting antiviral agents.
Multivariate analysis of factors predictive of hepatic decompensation after resection
|
|
|
|
|
| Age | 1.09 | 0.96-1.25 | 0.184 |
| Preoperative MELD score | 2.65 | 1.23-5.72 | 0.013 |
| Preoperative serum bilirubin | 0.15 | 0.01-3.63 | 0.242 |
| Clinically significant portal hypertension | |||
| No | Reference | Reference | 0.191 |
| Yes | 4.39 | 0.48-40.25 | |
| Tumor diameter (cm) | 5.42 | 1.99-14.77 | 0.001 |
| Hospital stay (d) | 2.49 | 1.46-4.22 | 0.001 |
| ICU admission | |||
| No | Reference | Reference | 0.448 |
| Yes | 0.42 | 0.05-3.92 |
P < 0.05.
P < 0.01.
CI: Confidence interval; MELD: Model for end-stage liver disease; OR: Odds ratio; ICU: Intensive care units.
Figure 11-, 2-, 3-, 4-, and 5-year survival after resection.
Univariate survival analysis of the predictors of survival in study population
| Mean survival time (mo) | 95%CI | Log-rank test |
| |
| Clinically significant portal hypertension | ||||
| No | 40.6 | 35.3-46 | 0.551 | 0.458 |
| Yes | 39.5 | 30.9-48.1 | ||
| Preoperative AFP > 400 ng/mL | ||||
| No | 43.9 | 38.3-49.5 | 8.787 | 0.003 |
| Yes | 24.6 | 14.1-35.2 | ||
| Preoperative MELD score | ||||
| < 10 | 46.38 | 41.13-51.63 | 19.209 | < 0.001 |
| 10-20 | 22.55 | 13.44-31.65 | ||
| BCLC stage | ||||
| 0 | 51.9 | 40.5-63.2 | 22.328 | < 0.001 |
| A | 47.9 | 42.1-53.6 | ||
| B | 26.1 | 18.3-33.8 | ||
| PHLF | ||||
| No | 47.1 | 41.4-52.8 | 8.489 | 0.004 |
| Yes | 32.1 | 24.8-39.4 | ||
| PHLF grade | ||||
| Absent | 47.1 | 41.4-52.8 | 114.117 | < 0.001 |
| A | 42.2 | 30.4-53.9 | ||
| B | 31.7 | 23-40.4 | ||
| C | 2.1 | 0.5-3.6 | ||
| 50-50 criteria | ||||
| Absent | 43.6 | 38.8-48.3 | 156.853 | < 0.001 |
| Present | 0.8 | 0.7-0.8 | ||
| Post-operative MELD score | ||||
| ≤ 10 | 49.3 | 43.4-55.3 | 12.29 | < 0.001 |
| > 10 | 32.7 | 25.8-39.7 | ||
| Post-operative decompensation | ||||
| No | 52.2 | 47.1-57.4 | 27.716 | < 0.001 |
| Yes | 28.3 | 21.1-35.5 | ||
| HCC recurrence | ||||
| No | 53.3 | 48.7-57.9 | 69.639 | < 0.001 |
| Yes | 13.2 | 9.6-16.8 |
P < 0.01.
P < 0.001.
AFP: Alpha-fetoprotein; BCLC: Barcelona clinic liver cancer; CI: Confidence interval; HCC: Hepatocellular carcinoma; MELD: Model for end-stage liver disease; PHLF: Post-hepatectomy liver failure.
Multivariate analysis of independent prognostic factors for the survival of patients after the liver resection surgery for hepatocellular carcinoma
|
|
|
|
|
| Age (yr) | 1.02 | 0.96-1.08 | 0.493 |
| Preoperative MELD score | 1.37 | 1.16-1.62 | < 0.001 |
| Preoperative AFP (ng/mL) | 1.001 | 1-1.002 | 0.08 |
| BCLC stage | |||
| 0 | Reference | Reference | 0.757 |
| A | 0.59 | 0.12-2.91 | |
| B | 0.45 | 0.06-3.65 | |
| PHLF grade | |||
| Absent | Reference | Reference | < 0.001 |
| A | 2.33 | 0.59-9.24 | |
| B | 3.15 | 1.11-8.95 | |
| C | 373.41 | 66.23-2105.43 | |
| Postoperative MELD score > 10 | 1.03 | 0.39-2.67 | 0.958 |
| Postoperative decompensation | 2.03 | 0.64-6.46 | 0.23 |
| HCC recurrence | 11.67 | 4.19-32.52 | < 0.001 |
P < 0.001.
AFP: alpha-fetoprotein; BCLC: Barcelona clinic liver cancer; CI: Confidence interval; HCC: Hepatocellular carcinoma; HR: Hazard ratio; MELD: Model for end-stage liver disease; PHLF: Post-hepatectomy liver failure.